STOCK TITAN

[6-K] TRINITY BIOTECH PLC Current Report (Foreign Issuer)

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
6-K
Rhea-AI Filing Summary

Trinity Biotech plc filed a Form 6-K announcing two administrative updates. Shareholders approved amendments to the Company’s Constitution at the Annual General Meeting held on September 30, 2025. The Company and certain subsidiaries also executed an amendment to the credit agreement governing their term loan facility with Perceptive Credit Holdings III, L.P.

The amended Constitution is filed as Exhibit 99.1, and the First Amendment to the Sixth Amended and Restated Credit Agreement and Guaranty, dated October 16, 2025, is filed as Exhibit 99.2. This Form 6-K is incorporated by reference into the Company’s existing Form S-8 registration statements.

Trinity Biotech plc ha presentato un modulo 6-K annunciando due aggiornamenti amministrativi. Gli azionisti hanno approvato le modifiche allo Statuto della Società durante l'Assemblea Generale Annuale tenutasi il 30 settembre 2025. La Società e alcune controllate hanno inoltre stipulato una modifica all'accordo di credito che regola la loro linea di prestito a termine con Perceptive Credit Holdings III, L.P.

Lo Statuto modificato è presentato come Esibizione 99.1, e la Prima Modifica al Sesto Accordo Modificato e Riaffermato sul Credito e la Garanzia, con data 16 ottobre 2025, è presentata come Esibizione 99.2. Questo Form 6-K è incorporato per riferimento nelle esistenti dichiarazioni di registrazione Form S-8 della Società.

Trinity Biotech plc presentó un Formulario 6-K anunciando dos actualizaciones administrativas. Los accionistas aprobaron en la Junta General Anual celebrada el 30 de septiembre de 2025 enmiendas al Estatuto de la Compañía. La Compañía y ciertas subsidiarias también firmaron una enmienda al acuerdo de crédito que rige su facilidad de préstamo a plazo con Perceptive Credit Holdings III, L.P.

El Estatuto enmendado se presenta como Exhibit 99.1, y la Primera Enmienda al Sexto Acordo de Crédito Modificado y Restablecido y a la Garantía, con fecha del 16 de octubre de 2025, se presenta como Exhibit 99.2. Este Formulario 6-K está incorporado por referencia a las declaraciones de registro Form S-8 existentes de la Compañía.

Trinity Biotech plc가 두 가지 행정 업데이트를 발표하는 Form 6-K를 제출했습니다. 주주들은 2025년 9월 30일에 열린 연례 주주총회에서 회사의 정관 수정안을 승인했습니다. 회사와 특정 자회사들은 또한 Perceptive Credit Holdings III, L.P.와의 기간 대출 시설을 관리하는 신용계약에 대한 수정안을 체결했습니다.

수정된 정관은 Exhibit 99.1로 제출되며, 2025년 10월 16일자로 작성된 제6차 수정 및 재확인 신용계약 및 보증에 대한 제1 수정안은 Exhibit 99.2로 제출됩니다. 이 Form 6-K는 회사의 기존 Form S-8 등록 명세서에 참조로 포함되어 있습니다.

Trinity Biotech plc a déposé un Form 6-K annonçant deux mises à jour administratives. Les actionnaires ont approuvé les amendements au statut de la société lors de l’assemblée générale annuelle qui s’est tenue le 30 septembre 2025. La société et certaines filiales ont également conclu un avenant à l’accord de crédit régissant leur facilité de prêt à terme avec Perceptive Credit Holdings III, L.P.

Le statut modifié est déposé comme Exhibit 99.1, et la Premier Amendement au Sixième Contrat de Crédit Modifié et Restitué et la Garantie, daté du 16 octobre 2025, est déposée comme Exhibit 99.2. Ce Form 6-K est incorporé par référence dans les déclarations d’enregistrement Form S-8 existantes de la société.

Trinity Biotech plc hat ein Formular 6-K eingereicht, das zwei administrativen Aktualisierungen bekannt gibt. Die Aktionäre genehmigten die Änderungen der Satzung der Gesellschaft auf der am 30. September 2025 abgehaltenen Hauptversammlung. Die Gesellschaft und bestimmte Tochtergesellschaften schlossen außerdem eine Änderung der Kreditvereinbarung ab, die ihre Term Loan Facility mit Perceptive Credit Holdings III, L.P. regelt.

Die geänderte Satzung ist als Exhibit 99.1 eingereicht, und die Erste Änderung zum Sechsfach geänderten und neu formulierten Kreditvertrag und Garantie, datiert auf den 16. Oktober 2025, ist als Exhibit 99.2 eingereicht. Dieses Form 6-K wird durch Bezug in die bestehenden Form S-8 Registrierungserklärungen der Gesellschaft aufgenommen.

Trinity Biotech plc قدّمت نموذج Form 6-K معلنًا عن تحديثين إداريين. وافق المساهمون على تعديلات على دستور الشركة في الاجتماع العام السنوي الذي عُقد في 30 سبتمبر 2025. كما وقّعت الشركة وبعض الشركات التابعة لها تعديلًا على اتفاقية الائتمان التي تحكم تسهيل القرض النهائي الخاص بها مع Perceptive Credit Holdings III, L.P.

يُقدَّم الدستور المعدل كمكوّن Exhibit 99.1، وتُقدَّم التعديل الأول على عقد الائتمان السادس المعدل والمُعاد صياغته والضمان، بتاريخ 16 أكتوبر 2025، كمكوّن Exhibit 99.2. تُدرَج هذه الفورم 6-K بالإشارة إلى بيانات التسجيل Form S-8 القائمة للشركة.

Positive
  • None.
Negative
  • None.

Trinity Biotech plc ha presentato un modulo 6-K annunciando due aggiornamenti amministrativi. Gli azionisti hanno approvato le modifiche allo Statuto della Società durante l'Assemblea Generale Annuale tenutasi il 30 settembre 2025. La Società e alcune controllate hanno inoltre stipulato una modifica all'accordo di credito che regola la loro linea di prestito a termine con Perceptive Credit Holdings III, L.P.

Lo Statuto modificato è presentato come Esibizione 99.1, e la Prima Modifica al Sesto Accordo Modificato e Riaffermato sul Credito e la Garanzia, con data 16 ottobre 2025, è presentata come Esibizione 99.2. Questo Form 6-K è incorporato per riferimento nelle esistenti dichiarazioni di registrazione Form S-8 della Società.

Trinity Biotech plc presentó un Formulario 6-K anunciando dos actualizaciones administrativas. Los accionistas aprobaron en la Junta General Anual celebrada el 30 de septiembre de 2025 enmiendas al Estatuto de la Compañía. La Compañía y ciertas subsidiarias también firmaron una enmienda al acuerdo de crédito que rige su facilidad de préstamo a plazo con Perceptive Credit Holdings III, L.P.

El Estatuto enmendado se presenta como Exhibit 99.1, y la Primera Enmienda al Sexto Acordo de Crédito Modificado y Restablecido y a la Garantía, con fecha del 16 de octubre de 2025, se presenta como Exhibit 99.2. Este Formulario 6-K está incorporado por referencia a las declaraciones de registro Form S-8 existentes de la Compañía.

Trinity Biotech plc가 두 가지 행정 업데이트를 발표하는 Form 6-K를 제출했습니다. 주주들은 2025년 9월 30일에 열린 연례 주주총회에서 회사의 정관 수정안을 승인했습니다. 회사와 특정 자회사들은 또한 Perceptive Credit Holdings III, L.P.와의 기간 대출 시설을 관리하는 신용계약에 대한 수정안을 체결했습니다.

수정된 정관은 Exhibit 99.1로 제출되며, 2025년 10월 16일자로 작성된 제6차 수정 및 재확인 신용계약 및 보증에 대한 제1 수정안은 Exhibit 99.2로 제출됩니다. 이 Form 6-K는 회사의 기존 Form S-8 등록 명세서에 참조로 포함되어 있습니다.

Trinity Biotech plc a déposé un Form 6-K annonçant deux mises à jour administratives. Les actionnaires ont approuvé les amendements au statut de la société lors de l’assemblée générale annuelle qui s’est tenue le 30 septembre 2025. La société et certaines filiales ont également conclu un avenant à l’accord de crédit régissant leur facilité de prêt à terme avec Perceptive Credit Holdings III, L.P.

Le statut modifié est déposé comme Exhibit 99.1, et la Premier Amendement au Sixième Contrat de Crédit Modifié et Restitué et la Garantie, daté du 16 octobre 2025, est déposée comme Exhibit 99.2. Ce Form 6-K est incorporé par référence dans les déclarations d’enregistrement Form S-8 existantes de la société.

Trinity Biotech plc hat ein Formular 6-K eingereicht, das zwei administrativen Aktualisierungen bekannt gibt. Die Aktionäre genehmigten die Änderungen der Satzung der Gesellschaft auf der am 30. September 2025 abgehaltenen Hauptversammlung. Die Gesellschaft und bestimmte Tochtergesellschaften schlossen außerdem eine Änderung der Kreditvereinbarung ab, die ihre Term Loan Facility mit Perceptive Credit Holdings III, L.P. regelt.

Die geänderte Satzung ist als Exhibit 99.1 eingereicht, und die Erste Änderung zum Sechsfach geänderten und neu formulierten Kreditvertrag und Garantie, datiert auf den 16. Oktober 2025, ist als Exhibit 99.2 eingereicht. Dieses Form 6-K wird durch Bezug in die bestehenden Form S-8 Registrierungserklärungen der Gesellschaft aufgenommen.



SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549



F O R M 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of October 2025

TRINITY BIOTECH PLC
(Name of Registrant)

IDA Business Park
Bray, Co. Wicklow, Ireland
(Address of Principal Executive Office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F     Form 40-F

This Form 6-K is being incorporated by reference into our Registration Statements on Form S-8 (File Nos. 333-182279, 333-195232 and 333-253070).



 EXPLANATORY NOTE

At the Company’s Annual General Meeting held on September 30, 2025, shareholders approved resolutions that resulted in amendments to the Company’s Constitution. The results of these resolutions were disclosed in the Form 6-K filed on September 30, 2025. The Company and certain of its subsidiaries also amended the credit agreement governing the companies’ term loan facility with Perceptive Credit Holdings III, L.P. Copies of the amended Company Constitution and the amendment to the credit agreement are filed herewith as Exhibits 99.1 and 99.2. The foregoing description of the credit agreement is a general description only, does not purport to be complete, and is qualified in its entirety by reference to the terms of the credit agreement attached hereto as Exhibit 99.2, which is incorporated herein by reference.


EXHIBIT INDEX

Exhibit

Description
99.1

Trinity Biotech Constitution 30 September 2025
99.2

First Amendment to Sixth Amended and Restated Credit Agreement and Guaranty, dated as of October 16, 2025.



SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 
TRINITY BIOTECH PLC
 
 
 
Trinity Biotech plc
 
 
 
(Registrant)
 
 
 
 
 
 
By:
/s/ Susan O’Connor
 
 
 
Susan O’Connor
 
 
 
Interim Chief Financial Officer
 

Date:  October 23, 2025


Trinity Biotech Plc

NASDAQ:TRIB

TRIB Rankings

TRIB Latest News

TRIB Latest SEC Filings

TRIB Stock Data

3.53M
2.92M
12.01%
13.95%
7.12%
Medical Devices
Healthcare
Link
Ireland
Bray